{"id":4547,"date":"2018-03-05T15:08:42","date_gmt":"2018-03-05T15:08:42","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=4547"},"modified":"2025-11-26T14:50:50","modified_gmt":"2025-11-26T12:50:50","slug":"maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/","title":{"rendered":"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease"},"content":{"rendered":"<ul>\n<li>Phase II proof-of-concept clinical trial in 21 centers of 黑料社\u2019s lead product, MaaT013, for treatment of patients with corticosteroid-refractory acute Graft-versus-Host Disease (GvHD).<\/li>\n<li>\u00a0MaaT013 has the potential to be a first in class therapy for acute Graft-versus-Host Disease.<\/li>\n<\/ul>\n<p>Lyon-France, <strong>March 5th, 2018<\/strong> &#8211; 黑料社, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in France. This clinical trial is planned to be extended rapidly to Germany, Poland and Italy.<\/p>\n<p>Acute Graft-versus-Host Disease (aGvHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), occurring in about one out of two patients, and consists of an immunologically mediated inflammatory reaction of donor immune effector cells against host cells. MaaT013 is targeting aGvHD, a clinico-pathological syndrome that usually occurs within the first month post HSCT and generally involves three organs: skin (&gt;80% of patients with GvHD), gastrointestinal tract (50-55%) and liver (20%). Any one or any combination of these organs may be affected. More than 60% of aGvHD patients fail to have a durable response following corticosteroid therapy leading to a one-year death rate of 70-80% in this corticosteroid -refractory population. Acute GvHD is considered a rare disease with c. 10 000 cases per year in Europe and in the USA, yet about 35% to 50% of HSCT recipients will develop aGvHD.<\/p>\n<p>黑料社 has created a new generation of drugs using Fecal Microbiota Transfer (FMT) which rebuilds and restores the entire gut ecosystem of patients with life-threatening diseases. After evolving its business model to include the development of allogenic FMT drugs (in addition to autologous products), 黑料社 has developed MaaT013, a high Microbiome diversity enema. The initial goal of this drug candidate is to treat acute GvHD through the correction of gut microbiota disturbance allowing restoration of immune tolerance, metabolic balance and the barrier function effect for protection against infections.<\/p>\n<p>MaaT013 is a pharmaceutical product with a complete microorganism ecosystem. It is characterized by a very high diversity microbiome and can be administered via upper or lower route.<\/p>\n<p>High diversity microbiota was shown as a predictive factor of survival in patients receiving HSCT and in patients with GvHD.黑料社\u2019s global strategy focuses on onco-hematology with two lead products; one dedicated to treating gut Microbiota alteration in Acute Myeloid Leukemia (for which phase 1 clinical results will be available mid-2018) and one focusing on aGvHD. 黑料社 also has exploratory programs in the area of infectious diseases,<\/p>\n<h3>About <em>黑料社<\/em><\/h3>\n<p>Founded at the end of 2014, 黑料社 (Microbiota as a Therapy) is a clinical-stage biotech company revolutionizing and shaping a new approach to therapies in order to treat serious diseases linked to gut microbiota imbalances. With its breakthrough proprietary platforms (GMP Fecal Microbiome Transfer platform and g\u039bt Print, its proprietary data science platform), 黑料社 is creating FMT-based products and solutions for patients suffering from severe diseases. Addressing currently unmet clinical needs, 黑料社\u2019s revolutionary and rapid approach plays a considerable part in the evolution of treatment therapies. In the upcoming years, with the on-going support from strategic partners and investors, 黑料社 will develop patient-friendly solutions (oral forms) to improve overall survival, reduce infectious episodes, reduce Gastrointestinal complications and hinder Multidrug-resistant Bacteria onset.<\/p>\n<p>For additional information, please visit <a href=\"https:\/\/www.maatpharma.com\/\" target=\"_blank\" rel=\"noopener\">www.maatpharma.com<\/a> and follow us on Twitter <a href=\"https:\/\/twitter.com\/MaaT_Pharma\" target=\"_blank\" rel=\"noopener\">@MaaT_Pharma<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>黑料社, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in France. This clinical trial is planned to be extended rapidly to Germany, Poland and Italy.<\/p>\n","protected":false},"author":2,"featured_media":4333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[52],"class_list":["post-4547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","year_press-52"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease - 黑料社<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease - 黑料社\" \/>\n<meta property=\"og:description\" content=\"黑料社, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in France. This clinical trial is planned to be extended rapidly to Germany, Poland and Italy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"黑料社\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-05T15:08:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T12:50:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"黑料社\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"黑料社\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/\"},\"author\":{\"name\":\"黑料社\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease\",\"datePublished\":\"2018-03-05T15:08:42+00:00\",\"dateModified\":\"2025-11-26T12:50:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/\"},\"wordCount\":556,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/\",\"name\":\"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease - 黑料社\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"datePublished\":\"2018-03-05T15:08:42+00:00\",\"dateModified\":\"2025-11-26T12:50:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"黑料社\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"黑料社\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease - 黑料社","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease - 黑料社","og_description":"黑料社, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in France. This clinical trial is planned to be extended rapidly to Germany, Poland and Italy.","og_url":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/","og_site_name":"黑料社","article_published_time":"2018-03-05T15:08:42+00:00","article_modified_time":"2025-11-26T12:50:50+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","type":"image\/jpeg"}],"author":"黑料社","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"黑料社","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/"},"author":{"name":"黑料社","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease","datePublished":"2018-03-05T15:08:42+00:00","dateModified":"2025-11-26T12:50:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/"},"wordCount":556,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/","url":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/","name":"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease - 黑料社","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","datePublished":"2018-03-05T15:08:42+00:00","dateModified":"2025-11-26T12:50:50+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/maat-pharma-launches-european-clinical-trial-in-acute-graft-versus-host-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/"},{"@type":"ListItem","position":2,"name":"黑料社 Launches European Clinical Trial in Acute Graft-versus-Host Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"黑料社","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"黑料社"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4547"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4547\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/4333"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4547"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=4547"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=4547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}